AGIX KraneShares Artificial Intelligence ETF

ATLANTA, March 28 /PRNewswire-FirstCall/ -- AtheroGenics, Inc. (NASDAQ:AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that Walker Anderson Long, M.D. has joined the company as Vice President of Clinical Research. Dr. Long will be responsible for AtheroGenics' clinical research operations and various aspects related to bringing AtheroGenics' ARISE Phase III clinical trial to completion. Dr. Long will report directly to Rob Scott, M.D., Senior Vice President of Clinical Development and Regulatory Affairs and Chief Medical Officer of AtheroGenics. (Logo: http://www.newscom.com/cgi-bin/prnh/20040730/ATATHEROGENICSLOGO ) "We are extremely pleased to have Walker join the AtheroGenics clinical team," said Dr. Scott. "As we progress with our ARISE Phase III study, Walker's outstanding record of accomplishment in global clinical research and drug development will be invaluable." Prior to joining AtheroGenics, Dr. Long served as Senior Vice President, Worldwide Project Operations at Cato Research, a full-service contract research and development firm focused on providing regulatory and clinical services to the life sciences industries. At Cato, Dr. Long was responsible for the strategic and operational aspects of all the drug development programs conducted for Cato's clients, including filing a number of successful New Drug Applications. Prior to his tenure at Cato Research, Dr. Long served as associate professor of pediatrics in the School of Medicine at the University of North Carolina at Chapel Hill. Dr. Long also served in a number of senior clinical research positions at Burroughs Welcome Co. (now GlaxoSmithKline) for a period of ten years, during which time his research resulted in the approvals of two life-saving medications by the FDA as well as a number of national and international honors. Dr. Long has authored 200 professional publications and holds four patents, one of which is the foundation patent of United Therapeutics. Dr. Long earned his undergraduate and medical degrees from the University of North Carolina. He did a residency in medicine and pediatrics at the University of North Carolina Hospitals, followed by fellowships in neonatology and pediatric cardiology at the University of North Carolina School of Medicine. Dr. Long stated, "I am truly excited to join the very capable drug development team at AtheroGenics, and to have the privilege of working on what could be a very important breakthrough in the treatment heart disease, the number one killer in the United States." About AtheroGenics AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The Company has two drug development programs currently in the clinic. AtheroGenics' lead compound, AGI-1067, is being evaluated in the pivotal Phase III ARISE clinical trial as an oral therapy for the treatment of atherosclerosis in collaboration with AstraZeneca. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant(R) technology. For more information about AtheroGenics, please visit http://www.atherogenics.com/. http://www.newscom.com/cgi-bin/prnh/20040730/ATATHEROGENICSLOGO http://photoarchive.ap.org/ DATASOURCE: AtheroGenics, Inc. CONTACT: Mark P. Colonnese, Chief Financial Officer, +1-678-336-2511, or Donna L. Glasky, Corporate Communications, +1-678-336-2517, or , both of AtheroGenics, Inc.; or Investor Relations, Lilian Stern of Stern Investor Relations, Inc., +1-212-362-1200, or Web site: http://www.atherogenics.com/

Copyright